There are a number of treatment choices available to treat patients with breast cancer and diagnostic tests can assist in the decision making, according to Adam M. Brufsky, MD, PhD, co-director of the Comprehensive Breast Cancer Center at University of Pittsburgh.
There are a number of treatment choices available to treat patients with breast cancer and diagnostic tests can assist in the decision making, according to Adam M. Brufsky, MD, PhD, co-director of the Comprehensive Breast Cancer Center at University of Pittsburgh.
Transcript
How do you decide between chemotherapy, endocrine therapy, or targeted therapy for your patients? What role do diagnostic tests play in your treatment decisions?
The way I decide between chemotherapy and endocrine therapy really in early-stage breast cancer is number 1, using the estrogen receptor and number 2 I really think that a lot of use of multi parametric genomic tests, such as MammaPrint, Oncotype, EndoPredict, that sort of thing, to help us make clinical decisions as to whether someone should get chemotherapy or not based on their risk.
In late-stage breast cancer, it also is estrogen receptor positivity. It’s HER2 positivity. And I think that even as people get further along in their clinical course and have gone through multiple therapies a lot us are really starting to incorporate sematic DNA testing on these patients to try to find ESR, estrogen receptor, mutations. Potentially, HER2 tyrosine kinase mutations to help us figure out how to best treat these patients. Although those things are kind of experimental at this point, I think generally what I tend to use is estrogen receptor, HER2, how much disease the patient has, for example, I’ll decide between hormone therapy, receptor base, or HER2-base therapy in chemotherapy.
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Access Denied: CMS’ Action Hurts Patients With Cancer in Rural America
May 6th 2024CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.
Read More